Sodium diethyldithiocarbamate influences the early immunological changes evoked by an acute non-antigenic inflammation process.
Calcium pyrophosphate (CaPp) produces an acute local inflammatory process when administered intra-pleurally. It is the simplest model of an inflammation uncomplicated by pharmacological properties of the agent or the presence of an antigen. Spleen or lymph-node T- or B-cell numbers and activities, including NK activity, are modified within 2 h under these conditions. A treatment with sodium diethyldithiocarbamate (lmuthiol), already known as a T-cell augmenting agent, restores towards normal values both the inflammatory reaction and the modified immune parameters induced in mice by CaPp pleurisy. The use of lmuthiol as a non-toxic, non-steroidal antiinflammatory agent is therefore suggested.
D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D002131:Calcium Pyrophosphate; D004050:Ditiocarb / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology*; D007694:Killer Cells, Natural / Q000276:immunology; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D051379:Mice; D008810:Mice, Inbred C57BL; D010998:Pleurisy / Q000139:chemically induced / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D013859:Thiocarbamates / Q000494:pharmacology*
D013859:Thiocarbamates; D004050:Ditiocarb; D002131:Calcium Pyrophosphate